secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001493152-25-009442
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics Health appoints Brian Norton as CEO, partners with Protega to distribute ROXYBOND
--------------------------------------------------------------------------------

- Brian Norton promoted to CEO, succeeding Timothy Canning; no disagreement cited.
- Norton's employment agreement: $490k base salary, performance bonus up to 100%, 9M RSUs vesting over 3 years.
- Wellgistics LLC collaborates with Protega to distribute ROXYBOND, the first FDA-approved abuse-deterrent IR opioid.
- Collaboration includes pharmacist education on abuse-deterrent options and regulatory compliance.
- Wellgistics serves over 5,400 independent pharmacies across all 50 states.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225009442/0001493152-25-009442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225009442/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer